These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8425197)

  • 1. Characterization of sarcoma cell lines from v-jun transgenic mice.
    Marshall GM; Vanhamme L
    Cancer Res; 1993 Feb; 53(3):622-6. PubMed ID: 8425197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor alpha and interleukin 1 alpha induce anchorage independence in v-jun transgenic murine cells.
    Vanhamme L; Marshall GM; Schuh AC; Breitman ML; Vogt PK
    Cancer Res; 1993 Feb; 53(3):615-21. PubMed ID: 8425196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional cell transformation by doxycycline-controlled expression of the ASV17 v-jun allele.
    Bader AG; Hartl M; Bister K
    Virology; 2000 Apr; 270(1):98-110. PubMed ID: 10772983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle arises as a late event during development of wound sarcomas in v-jun transgenic mice.
    Schuh AC; Keating SJ; Yeung MC; Breitman ML
    Oncogene; 1992 Apr; 7(4):667-76. PubMed ID: 1314368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice.
    Schuh AC; Keating SJ; Monteclaro FS; Vogt PK; Breitman ML
    Nature; 1990 Aug; 346(6286):756-60. PubMed ID: 2167455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
    Bader AG; Schneider ML; Bister K; Hartl M
    Oncogene; 2001 Nov; 20(51):7524-35. PubMed ID: 11709724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
    Basso J; Briggs J; Findlay C; Bos T
    Oncogene; 2000 Oct; 19(42):4876-85. PubMed ID: 11039905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
    Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts.
    Cohen SB; Waha A; Gelman IH; Vogt PK
    Oncogene; 2001 Jan; 20(2):141-6. PubMed ID: 11313943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos.
    Wang ZQ; Liang J; Schellander K; Wagner EF; Grigoriadis AE
    Cancer Res; 1995 Dec; 55(24):6244-51. PubMed ID: 8521421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jun, the oncoprotein.
    Vogt PK
    Oncogene; 2001 Apr; 20(19):2365-77. PubMed ID: 11402333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype.
    Iacovoni JS; Cohen SB; Berg T; Vogt PK
    Oncogene; 2004 Jul; 23(33):5703-6. PubMed ID: 15133497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation and inhibition of the AP-1 complex in human breast cancer cells.
    Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
    Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered growth and spontaneous transformation of cells cultured from v-jun transgenic mice recapitulate wound-induced multistage tumorigenesis.
    Schuh AC; Theodorescu D; Shalaby F; Breitman ML
    Cell Growth Differ; 1993 Mar; 4(3):177-84. PubMed ID: 8466856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences.
    Hadman M; Loo M; Bos TJ
    Oncogene; 1993 Jul; 8(7):1895-903. PubMed ID: 8510933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two distinct target cells for v-jun mediated wound tumorigenesis.
    Shalaby F; Schuh AC; Breitman ML
    Oncogene; 1994 Sep; 9(9):2579-88. PubMed ID: 8058321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rat embryo fibroblasts transformed by c-Jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors.
    Kraemer M; Tournaire R; Dejong V; Montreau N; Briane D; Derbin C; Binétruy B
    Cell Growth Differ; 1999 Mar; 10(3):193-200. PubMed ID: 10099833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors.
    Vial E; Perez S; Castellazzi M
    Oncogene; 2000 Oct; 19(43):5020-9. PubMed ID: 11042689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
    Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells.
    Li J; Johnson TA; Hanson LA; Beer DG
    Mol Carcinog; 1996 Aug; 16(4):213-20. PubMed ID: 8784464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.